UBS Downgrades Biogen (BIIB) to Neutral
Get Alerts BIIB Hot Sheet
Price: $215.63 -0.33%
Rating Summary:
29 Buy, 13 Hold, 0 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Rating Summary:
29 Buy, 13 Hold, 0 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
UBS downgraded Biogen (NASDAQ: BIIB) from Buy to Neutral with a price target of $242.00 (from $395.00).
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $226.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teleperformance (TEP:FP) (TLPFY) PT Lowered to EUR125 at RBC Capital, 'perceived risk profile makes it a no-fly zone for many investors'
- Goldman Sachs Downgrades Weibo Corp (WB) to Neutral
- Morgan Stanley Downgrades Sanbio Co Ltd. (4592:JP) (SNBIF) to Equalweight
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!